Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback